BioMérieux submitted a rapid multiplex syndromic vaginitis panel to the FDA for dual 510(k) clearance and CLIA waiver, aiming to bring point-of-care molecular results to women’s health settings. The BioFire SpotFire Vaginitis Panel (VG) is designed to deliver eight results from a single vaginal swab within about 20 minutes. The assay covers key bacterial vaginosis-associated bacterial species, multiple Lactobacillus species used as compositional signals, and Candida species plus Trichomonas vaginalis. BioMérieux said its algorithm-based approach includes assessment of relative bacterial abundance to distinguish underlying etiologies. Regulatory filing timing is positioned as a strategic step for the company’s expansion into women’s and sexual health diagnostics, with claimed clinical utility in guiding targeted prescribing and reducing unnecessary empiric treatment during the same visit.